Literature DB >> 10807682

Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin.

S Sbrenna1, M Marti, M Morari, G Calo', R Guerrini, L Beani, C Bianchi.   

Abstract

The modulation of [(3)H]-5-hydroxytryptamine ([(3)H]-5-HT) efflux from superfused rat cortical synaptosomes by delta, kappa, mu and ORL(1) opioid receptor agonists and antagonists was studied. Spontaneous [(3)H]-5-HT efflux was reduced (20% inhibition) by either 0.5 microM tetrodotoxin or Ca(2+)-omission. Ten mM K(+)-evoked [(3)H]-5-HT overflow was largely Ca(2+)-dependent (90%) and tetrodotoxin-sensitive (50%). The delta receptor agonist, deltorphin-I, failed to modulate the K(+)-evoked neurotransmitter efflux up to 0.3 microM. The kappa and the mu receptor agonists, U-50,488 and endomorphin-1, inhibited K(+)-evoked [(3)H]-5-HT overflow (EC(50)=112 and 7 nM, respectively; E(max)=28 and 29% inhibition, respectively) in a norBinaltorphimine- (0.3 microM) and naloxone- (1 microM) sensitive manner, respectively. None of these agonists significantly affected spontaneous [(3)H]-5-HT efflux. The ORL(1) receptor agonist nociceptin inhibited both spontaneous (EC(50)=67 nM) and K(+)-evoked (EC(50)=13 nM; E(max)=52% inhibition) [(3)H]-5-HT efflux. The effect of NC was insensitive to naloxone (up to 10 microM), but was antagonized by [Nphe(1)]nociceptin(1-13)NH(2) (a novel selective ORL(1) receptor antagonist; pA(2)=6.7) and by naloxone benzoylhydrazone (pA(2)=6.3). The ORL(1) ligand [Phe(1)psi(CH(2)-NH)Gly(2)]nociceptin(1-13)NH(2) also inhibited K(+) stimulated [(3)H]-5-HT overflow (EC(50)=64 nM; E(max)=31% inhibition), but its effect was partially antagonized by 10 microM naloxone. It is concluded that the ORL(1) receptor is the most important presynaptic modulator of neocortical 5-HT release within the opioid receptor family. This suggests that the ORL(1)/nociceptin system may have a powerful role in the control of cerebral 5-HT-mediated biological functions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807682      PMCID: PMC1572081          DOI: 10.1038/sj.bjp.0703321

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

Review 2.  Food cravings, endogenous opioid peptides, and food intake: a review.

Authors:  M E Mercer; M D Holder
Journal:  Appetite       Date:  1997-12       Impact factor: 3.868

3.  A new selective antagonist of the nociceptin receptor.

Authors:  R Guerrini; G Calo; A Rizzi; R Bigoni; C Bianchi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  1998-01       Impact factor: 8.739

Review 4.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology.

Authors:  D H Jenkinson; E A Barnard; D Hoyer; P P Humphrey; P Leff; N P Shankley
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

5.  A simple apparatus for studying the release of neurotransmitters from synaptosomes.

Authors:  M Raiteri; F Angelini; G Levi
Journal:  Eur J Pharmacol       Date:  1974-03       Impact factor: 4.432

6.  ORL-1 and mu opioid receptor antisera label different fibers in areas involved in pain processing.

Authors:  G Monteillet-Agius; J Fein; B Anton; C J Evans
Journal:  J Comp Neurol       Date:  1998-09-28       Impact factor: 3.215

7.  Pharmacological characterization of the nociceptin receptor mediating hyperphagia: identification of a selective antagonist.

Authors:  C Polidori; G Calo; R Ciccocioppo; R Guerrini; D Regoli; M Massi
Journal:  Psychopharmacology (Berl)       Date:  2000-03       Impact factor: 4.530

8.  Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15.

Authors:  J L Montiel; F Cornille; B P Roques; F Noble
Journal:  J Neurochem       Date:  1997-01       Impact factor: 5.372

9.  Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors.

Authors:  E Schlicker; S Werthwein; M Kathmann; U Bauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-10       Impact factor: 3.000

10.  ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

Authors:  C Mollereau; M Parmentier; P Mailleux; J L Butour; C Moisand; P Chalon; D Caput; G Vassart; J C Meunier
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

View more
  15 in total

1.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses.

Authors:  Bihua Bie; Wei Zhu; Zhizhong Z Pan
Journal:  J Pharmacol Exp Ther       Date:  2009-01-23       Impact factor: 4.030

3.  The effects of new nociceptin analogs on the behavior of white rats.

Authors:  E A Chesnokova; P K Anokhin; A S Voronkova; N Yu Sarycheva; V A Dubynin; A A Kamenskii; L A Andreeva; N F Myasoedov
Journal:  Dokl Biol Sci       Date:  2013-05-08

4.  Mapping neurotransmitter networks with PET: an example on serotonin and opioid systems.

Authors:  Lauri Tuominen; Lauri Nummenmaa; Liisa Keltikangas-Järvinen; Olli Raitakari; Jarmo Hietala
Journal:  Hum Brain Mapp       Date:  2013-05-14       Impact factor: 5.038

Review 5.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 6.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

7.  Direct and indirect inhibition by nociceptin/orphanin FQ on noradrenaline release from rodent cerebral cortex in vitro.

Authors:  Anna Siniscalchi; Donata Rodi; Michele Morari; Matteo Marti; Sabrina Cavallini; Silvia Marino; Lorenzo Beani; Clementina Bianchi
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

8.  Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.

Authors:  Matteo Marti; Donata Rodi; Qin Li; Remo Guerrini; Stefania Fasano; Ilaria Morella; Alessandro Tozzi; Riccardo Brambilla; Paolo Calabresi; Michele Simonato; Erwan Bezard; Michele Morari
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

Review 9.  Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  Elaine C Gavioli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

10.  Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi/o protein linked pathways.

Authors:  M Fantin; C Fischetti; C Trapella; M Morari
Journal:  Br J Pharmacol       Date:  2007-07-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.